Lupin and Sandoz Launch Biosimilar Ranibizumab Across Europe
Lupin Ltd 路 Press Release 路 12 Nov 2026, 5:08 pm
Lupin and Sandoz Launch Biosimilar Ranibizumab Across Europe Lupin announced on 12th Nov'26 that its commercial partner, Sandoz, launched Ranluspec (biosimilar Ranibizumab) across Europe, excluding Germany. The launch follows European Commission approval for vial and pre-filled syringe presentations. Ranluspec is indicated for retinal and choroidal vascular diseases, including wet age-related macular degeneration, diabetic macular edema, proliferative diabetic retinopathy, macular edema post-retinal vein occlusion, and choroidal neovascularization. The product rollout expands Lupin's biologic footprint in key European markets.
Original exchange filing (PDF)
More announcements from Lupin Ltd
- Transcript of Q2 FY2027 Earnings Conference Call. 路 07 Nov 2026
- Link of Audio recording of the Earnings Call-Q2 FY27. 路 05 Nov 2026
- Investor Presentation- Q2 FY2027 路 04 Nov 2026
- Lupin Q2 FY2027 Results 路 04 Nov 2026
- Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with .... 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Lupin Limited has submitted to the Exchange, the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
